ArticleScientific reports2025
A histopathology aware DINO model with attention based representation enhancement.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histopathological image analysis plays a critical role in modern medical diagnostics, particularly in the detection and classification of various types of cancer. This study proposes a method called HistoDARE (Histopathology-Aware DINO with Attention-based Representation Enhancement), which offers an innovative approach to the attention module used in the Vision Transformers architecture. Unlike conventional attention mechanisms, HistoDARE introduces a novel three-stage AttentionWrapper module that sequentially applies spatial and channel attention followed by a residual refinement stage, enabling the extraction of spatially-aware and semantically distinctive feature representations. HistoDARE is a method integrated into the DINOv2 model, which uses the ViT-L/14 architecture. The obtained features were interpreted using Logistic Regression, and 5-fold stratified cross-validation was applied on the NCT-CRC-HE-100K dataset. The proposed HistoDARE achieved a mean accuracy of 98.03%, precision of 98.03%, recall of 98.02%, F1-score of 98.02%, and specificity of 99.95%, outperforming the baseline DINOv2 and other state-of-the-art methods. The experiments were conducted on a computer with high computational capacity. Based on the DINOv2 architecture, the proposed HistoDARE maintains comparable computational efficiency and resource usage while generating more contextually enriched and discriminative feature representations. During performance measurements, it demonstrated consistent and stable improvements across all stages in all folds. Notably, significant performance improvements were achieved in clinically critical classes such as NORM and STR. These results demonstrate that HistoDARE not only achieves high overall accuracy but also provides superior class-level consistency, making it a robust and generalisable framework for clinical histopathology applications. The developed method has been shared on our GitHub repository. This ensures transparency in terms of reproducibility and supports its usability by other researchers on different datasets in the future. The core contribution of HistoDARE is a three-stage AttentionWrapper (spatial, channel, residual refinement) integrated into the DINOv2 ViT-L/14 backbone to make patch-level representations histopathology-aware. Despite the small numerical gain over a strong self-supervised baseline, this attention-enabled refinement yields statistically consistent improvements on clinically sensitive classes (NORM, STR) and thus strengthens the model's potential usability in real pathology workflows.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.